Abeona Therapeutics Inc. has announced a significant expansion in access to ZEVASKYN, marking the activation of Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center for this groundbreaking gene-modified cellular therapy, as reported by The Manilla Times. This milestone represents a crucial step forward for patients with recessive dystrophic epidermolysis bullosa (RDEB), particularly those on the east coast.
A New Frontier in RDEB Treatment
RDEB is a rare, severe blistering disorder that currently has no cure. The condition stems from a genetic defect affecting both copies of the COL7A1 gene, preventing patients from producing functional type VII collagen, the protein responsible for anchoring the dermal and epidermal layers of skin. Without this critical protein, patients experience chronic, painful blistering and wounds that struggle to heal, often leading to life-threatening complications.
ZEVASKYN (prademagene zamikeracel) represents a transformative approach to this devastating disease. As the first and only autologous cell sheet-based gene therapy for RDEB, ZEVASKYN works by incorporating the functional COL7A1 gene into patients’ own skin cells using a specialized retroviral vector. This innovative approach enables the patient’s own cells to produce functional type VII collagen in treated wounds, delivering clinically meaningful wound healing and pain reduction with a single surgical application.
Strategic Partnership with Industry Leaders
The partnership between Abeona and CHOP is particularly significant given the hospital’s reputation as a global leader in pediatric care and gene and cell therapy innovation. Dr. Marissa J. Perman, Section Chief of Dermatology and Director of the Epidermolysis Bullosa Multidisciplinary Clinic at CHOP, emphasized the hospital’s commitment to delivering cutting-edge treatments that enhance quality of life for RDEB patients and their families.
Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona, highlighted that expanding access to ZEVASKYN through CHOP “significantly advances” the RDEB community’s access to this therapy across the east coast region, representing a meaningful expansion of treatment options for families previously requiring travel to distant treatment centers.
Comprehensive Patient Support
Recognizing that access involves more than location, Abeona provides Abeona Assist, a comprehensive patient support program designed to alleviate barriers to treatment. The program offers personalized assistance including insurance benefit navigation, financial assistance options, and travel and logistical support, recognizing that gene therapy for rare diseases requires coordinated, multifaceted support.
Important Considerations
While ZEVASKYN offers unprecedented hope for RDEB patients, important safety considerations exist. Patients require lifelong monitoring for potential cancer development due to the therapy’s mechanism. Allergic reactions, including rare anaphylaxis, are possible, and the therapy involves human and animal materials that, while tested, carry inherent infection risks.
